H e m a t o lo g y E d u c a t io n - European Hematology Association
H e m a t o lo g y E d u c a t io n - European Hematology Association
H e m a t o lo g y E d u c a t io n - European Hematology Association
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Conclus<strong>io</strong>ns<br />
Chemoimmunotherapy has had a dramatic impact on<br />
the outcome of patients with CLL, has improved CR<br />
rates, eradicates minimal residual disease, and has<br />
resulted in improved survival. Remiss<strong>io</strong>ns with frontline<br />
therapy last for years and data are now emerging that<br />
more effective frontline regimens are associated with<br />
improved overall survival in CLL. Studies are also<br />
assessing whether specific treatments are indicated for<br />
groups of patients with specific cytogenetic abnormalities.<br />
However, not all patients can tolerate aggressive<br />
chemo-immunotherapy regimens, and patients continue<br />
to relapse so new drugs are needed to effect cure in<br />
these patient populat<strong>io</strong>ns. The encouraging array of<br />
ongoing clinical trials and investigat<strong>io</strong>nal drugs, many of<br />
which have novel mechanisms of act<strong>io</strong>n, engender great<br />
optimism that cure of CLL may be accomplished within<br />
the next 20 years.<br />
References<br />
1. Gribben JG. How I treat CLL up front. B<strong>lo</strong>od. 2010 Jan 14;115<br />
(2):187-97.<br />
2. Gribben JG, O’Brien S. Update on therapy of chronic lymphocytic<br />
leukemia. J Clin Oncol. 2011 Feb 10;29(5):544-50.<br />
3. Keating MJ, O’Brien S, Albitar M, Lerner S, Plunkett W, Giles F,<br />
et al. Early results of a chemoimmunotherapy regimen of fludarabine,<br />
cyc<strong>lo</strong>phosphamide, and rituximab as initial therapy<br />
for chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun<br />
20;23(18):4079-88.<br />
4. Tam CS, O’Brien S, Wierda W, Kantarjian H, Wen S, Do KA, et<br />
al. Long term results of the fludarabine, cyc<strong>lo</strong>phosphamide &<br />
rituximab regimen as initial therapy of chronic lymphocytic<br />
leukemia. B<strong>lo</strong>od. 2008 Apr 14.<br />
5. Wierda W, O’Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas<br />
D, et al. Chemoimmunotherapy with fludarabine, cyc<strong>lo</strong>phosphamide,<br />
and rituximab for relapsed and refractory chronic lymphocytic<br />
leukemia. J Clin Oncol. 2005 Jun 20;23(18):4070-8.<br />
6. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R,<br />
Mayer J, et al. Addit<strong>io</strong>n of rituximab to fludarabine and<br />
cyc<strong>lo</strong>phosphamide in patients with chronic lymphocytic<br />
leukaemia: a randomised, open-label, phase 3 trial. Lancet.<br />
2010 Oct 2;376(9747):1164-74.<br />
7. Stilgenbauer S, Dohner H. Campath-1H-induced complete<br />
remiss<strong>io</strong>n of chronic lymphocytic leukemia despite p53 gene<br />
mutat<strong>io</strong>n and resistance to chemotherapy. N Engl J Med. 2002<br />
Aug 8;347(6):452-3.<br />
8. Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J,<br />
Herbrecht R, et al. Phase III randomized study of bendamustine<br />
compared with ch<strong>lo</strong>rambucil in prev<strong>io</strong>usly untreated<br />
patients with chronic lymphocytic leukemia. J Clin Oncol.<br />
2009 Sep 10;27(26):4378-84.<br />
9. Gandhi V, Burger JA. Bendamustine in B-Cell Malignancies:<br />
The New 46-Year-Old Kid on the B<strong>lo</strong>ck. Clin Cancer Res. 2009<br />
Dec 15;15(24):7456-61.<br />
10. Fischer K, Cramer P, Stilgenbauer S. Bendamustine combined<br />
with rituximab (BR) in first-line therapy of advanced CLL: a<br />
multicenter phase II trial of the German CLL Study Group<br />
(GCLLSG). B<strong>lo</strong>od. 2009;114:89. Abstract 205.<br />
11. Schweighofer CD, Ritgen M, Eichhorst BF, Busch R, Abenhardt<br />
W, Kneba M, et al. Consolidat<strong>io</strong>n with alemtuzumab improves<br />
progress<strong>io</strong>n-free survival in patients with chronic lymphocytic<br />
leukaemia (CLL) in first remiss<strong>io</strong>n: <strong>lo</strong>ng-term fol<strong>lo</strong>w-up of a randomized<br />
phase III trial of the German CLL Study Group<br />
(GCLLSG). Br J Haematol. 2009 Jan;144(1):95-8.<br />
12. Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD,<br />
Hellmann A, et al. Ofatumumab as single-agent CD20<br />
immunotherapy in fludarabine-refractory chronic lymphocytic<br />
leukemia. J Clin Oncol. 2010 Apr 1;28(10):1749-55.<br />
13. Wierda WG, Kipps TJ, Dürig J. Ofatumumab combined with<br />
fludarabine and cyc<strong>lo</strong>phosphamide (O-FC) shows high activity<br />
in patients with prev<strong>io</strong>usly untreated chronic lymphocytic<br />
leukemia (CLL): results from a randomized, multicenter, internat<strong>io</strong>nal,<br />
two-dose, parallel group, phase II trial. B<strong>lo</strong>od. 2009;<br />
114:90. Abstract 207.<br />
London, United Kingdom, June 9-12, 2011<br />
14. Contri A, Brunati AM, Trentin L, Cabrelle A, M<strong>io</strong>rin M, Cesaro<br />
L, et al. Chronic lymphocytic leukemia B cells contain anoma<strong>lo</strong>us<br />
Lyn tyrosine kinase, a putative contribut<strong>io</strong>n to defective<br />
apoptosis. J Clin Invest. 2005 Feb;115(2):369-78.<br />
15. Amrein L, Hernandez TA, Ferrar<strong>io</strong> C, Johnston J, Gibson SB,<br />
Panasci L, et al. Dasatinib sensitizes primary chronic lymphocytic<br />
leukaemia lymphocytes to ch<strong>lo</strong>rambucil and fludarabine<br />
in vitro. Br J Haematol. 2008 Dec;143(5):698-706.<br />
16. Amrein PC, Attar EC, Takvorian RW, Hochberg EP, Ballen KK,<br />
Leahy KM, et al. Phase II Study of Dasatinib in Relapsed or<br />
Refractory Chronic Lymphocytic Leukemia. Clin Cancer Res.<br />
2011 Mar 14.<br />
17. Gobessi S, Laurenti L, Longo PG, Carsetti L, Berno V, Sica S, et<br />
al. Inhibit<strong>io</strong>n of constitutive and BCR-induced Syk activat<strong>io</strong>n<br />
downregulates Mcl-1 and induces apoptosis in chronic lymphocytic<br />
leukemia B cells. Leukemia. 2009 Apr;23(4):686-97.<br />
18. Suljagic M, Longo PG, Bennardo S, Perlas E, Leone G, Laurenti<br />
L, et al. The Syk inhibitor fostamatinib disodium (R788)<br />
inhibits tumor growth in the Emu- TCL1 transgenic mouse<br />
model of CLL by b<strong>lo</strong>cking antigen-dependent B-cell receptor<br />
signaling. B<strong>lo</strong>od. 2010 Dec 2;116(23):4894-905.<br />
19. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM,<br />
Lacasce A, et al. Inhibit<strong>io</strong>n of Syk with fostamatinib disodium<br />
has significant clinical activity in non-Hodgkin lymphoma and<br />
chronic lymphocytic leukemia. B<strong>lo</strong>od. 2010 Apr 1;115(13):<br />
2578-85.<br />
20. Herman SEM, Gordon AL, Mahoney E, Jag<strong>lo</strong>wski SM, Blum KA,<br />
Buggy J, et al. The Kinase Inhibitor, PCI-32765, Demonstrates<br />
Activity in Chronic Lymphcytic Leukemia Cells Independent of<br />
Microenvironmental Survival Signals. B<strong>lo</strong>od. 2010;116: Abstract<br />
1385.<br />
21. Burger J, O’Brien S, Fowler N, Advani R, Sharman JP, Furman<br />
RR, et al. The Bruton’s Tyrosine Kinase Inhibitor, PCI-32765, Is<br />
Well Tolerated and Demonstrates Promising Clinical Activity<br />
In Chronic Lymphocytic Leukemia (CLL) and Small<br />
Lymphcytic Lymphoma (SLL): An Update on Ongoing Phase 1<br />
Studies. B<strong>lo</strong>od. 2010;116:Abstract 57.<br />
22. Cuni S, Perez-Aciego P, Perez-Chacon G, Vargas JA, Sanchez A,<br />
Martin-Saavedra FM, et al. A sustained activat<strong>io</strong>n of PI3K/NFkappaB<br />
pathway is critical for the survival of chronic lymphocytic<br />
leukemia B cells. Leukemia. 2004 Aug;18(8):1391-400.<br />
23. Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B,<br />
Johnson AJ, et al. CAL-101, a p110delta selective phosphatidyl -<br />
inositol-3-kinase inhibitor for the treatment of B-cell malignancies,<br />
inhibits PI3K signaling and cellular viability. B<strong>lo</strong>od. 2011<br />
Jan 13;117(2):591-4.<br />
24. Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W,<br />
Flynn JM, et al. Phosphatidylinositol 3-kinase-delta inhibitor<br />
CAL-101 shows promising preclinical activity in chronic lymphocytic<br />
leukemia by antagonizing intrinsic and extrinsic cellular<br />
survival signals. B<strong>lo</strong>od. 2010 Sep 23;116(12):2078-88.<br />
25. Furman RR, Byrd JC, Brown JR, Coutre SE, Benson DMJ,<br />
Wagner-Johnston ND, et al. CAL-101, An Isoform-Selective<br />
Inhibitor of Phosphatidylinositol 3-Kinase P110d, Demonstrates<br />
Clinical Activity and Pharmacodynamic Effects In Patients with<br />
Relapsed or Refractory Chronic Lymphocytic Leukemia. B<strong>lo</strong>od.<br />
2010;116:Abstract 55.<br />
26. Flinn IW, Schreeder MT, Wagner-Johnson ND, Boccia RV,<br />
Leonard JP, Courte SE, et al. A Phase 1 Study of CAL-101, An<br />
Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase<br />
P110d, In Combinat<strong>io</strong>n with Rituximab and/or Bendamustine<br />
In Patients with Relapsed or Refractory B-cell Malignancies.<br />
B<strong>lo</strong>od. 2010;116:Abstract 2832.<br />
27. Gribben JG, Hosing C, Ma<strong>lo</strong>ney DG. Stem cell transplantat<strong>io</strong>n<br />
for indolent lymphoma and chronic lymphocytic leukemia.<br />
B<strong>io</strong>l B<strong>lo</strong>od Marrow Transplant. 2011 Jan;17(1 Suppl):S63-70.<br />
28. Dreger P, Corradini P, Kimby E, Michallet M, Milligan D,<br />
Schetelig J, et al. Indicat<strong>io</strong>ns for al<strong>lo</strong>geneic stem cell transplantat<strong>io</strong>n<br />
in chronic lymphocytic leukemia: the EBMT transplant<br />
consensus. Leukemia. 2007 Jan;21(1):12-7.<br />
29. Gribben JG. One step back but 2 steps forward. B<strong>lo</strong>od. 2009<br />
Oct 15;114(16):3359-60.<br />
30. Eichhorst BF, Busch R, Stilgenbauer S, Stauch M, Bergmann MA,<br />
Ritgen M, et al. First line therapy with fludarabine compared to<br />
ch<strong>lo</strong>rambucil does not result in a major benefit for elderly patients<br />
with advanced chronic lymphocytic leukemia. B<strong>lo</strong>od. 2009 Jul 15.<br />
31. Tsimberidou AM, O’Brien S, Khouri I, Giles FJ, Kantarjian HM,<br />
Champlin R, et al. Clinical outcomes and prognostic factors in<br />
patients with Richter’s syndrome treated with chemotherapy or<br />
chemoimmunotherapy with or without stem-cell transplantat<strong>io</strong>n.<br />
J Clin Oncol. 2006 May 20;24(15):2343-51.<br />
Hemato<strong>lo</strong>gy Educat<strong>io</strong>n: the educat<strong>io</strong>n programme for the annual congress of the <strong>European</strong> Hemato<strong>lo</strong>gy Associat<strong>io</strong>n | 2011; 5(1) | 103 |